Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283499 · ClinicalTrials.gov registry record · Phase 3
Opioid Analgesic Reduction Study (OARS) - Pilot
A Phase 3 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT05283499: Completed Phase 3 study, sponsored by Rutgers, The State University of New Jersey.
NCT05283499 is a Phase 3 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 53 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283499, a Phase 3 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to test protocols being developed for the conduct of a large sale multi-site clinical trial which will compare opioids to non-opioids for managing post-surgical impacted 3rd molar extraction pain.
Primary Outcome
Average Pain (self reported by subject) rated on numeric rating scale (0=no pain, 10=worst pain imaginable)
Interventions
- DRUG OPIOID
- DRUG NON-OPIOID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2021-03-26 |
| Phase | Phase 3 |
What the finished NCT05283499 record still lists
NCT05283499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which OPIOID is the first listed.
NCT05283499 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05283499 about?
NCT05283499 is a clinical study titled "Opioid Analgesic Reduction Study (OARS) - Pilot". The purpose of this study is to test protocols being developed for the conduct of a large sale multi-site clinical trial which will compare opioids to non-opioids for managing post-surgical impacted 3rd molar extraction pain.
What is the current status of trial NCT05283499?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 2020-07-06. Estimated completion is 2021-03-26.
What interventions are being tested in trial NCT05283499?
The interventions under investigation include: OPIOID (DRUG), NON-OPIOID (DRUG).
Who is sponsoring clinical trial NCT05283499?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05283499's enrollment target sits among peer trials
53 1839th of 2000 higher than 160 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI